全文获取类型
收费全文 | 6396篇 |
免费 | 822篇 |
国内免费 | 65篇 |
专业分类
耳鼻咽喉 | 109篇 |
儿科学 | 111篇 |
妇产科学 | 88篇 |
基础医学 | 256篇 |
口腔科学 | 122篇 |
临床医学 | 645篇 |
内科学 | 1052篇 |
皮肤病学 | 55篇 |
神经病学 | 307篇 |
特种医学 | 131篇 |
外国民族医学 | 1篇 |
外科学 | 750篇 |
综合类 | 416篇 |
预防医学 | 2013篇 |
眼科学 | 56篇 |
药学 | 742篇 |
2篇 | |
中国医学 | 37篇 |
肿瘤学 | 390篇 |
出版年
2024年 | 6篇 |
2023年 | 125篇 |
2022年 | 153篇 |
2021年 | 261篇 |
2020年 | 314篇 |
2019年 | 384篇 |
2018年 | 378篇 |
2017年 | 364篇 |
2016年 | 264篇 |
2015年 | 265篇 |
2014年 | 398篇 |
2013年 | 580篇 |
2012年 | 362篇 |
2011年 | 404篇 |
2010年 | 311篇 |
2009年 | 275篇 |
2008年 | 291篇 |
2007年 | 315篇 |
2006年 | 259篇 |
2005年 | 236篇 |
2004年 | 230篇 |
2003年 | 185篇 |
2002年 | 179篇 |
2001年 | 147篇 |
2000年 | 102篇 |
1999年 | 85篇 |
1998年 | 71篇 |
1997年 | 50篇 |
1996年 | 61篇 |
1995年 | 35篇 |
1994年 | 21篇 |
1993年 | 33篇 |
1992年 | 18篇 |
1991年 | 25篇 |
1990年 | 21篇 |
1989年 | 14篇 |
1988年 | 11篇 |
1987年 | 10篇 |
1986年 | 4篇 |
1985年 | 4篇 |
1984年 | 12篇 |
1983年 | 3篇 |
1982年 | 6篇 |
1981年 | 1篇 |
1980年 | 5篇 |
1979年 | 2篇 |
1978年 | 1篇 |
1976年 | 2篇 |
排序方式: 共有7283条查询结果,搜索用时 15 毫秒
1.
《The Journal of hand surgery》2022,47(8):752-761.e1
2.
Ehsan Zarei Elmira Madarshahian Adeleh Nikkhah Soheila Khodakarim 《Journal of tissue viability》2019,28(2):70-74
Background and objective
Pressure ulcer (PU) is one of the important and frequent complications of hospitalization, associated with high treatment costs. The present study was conducted to determine the incidence of PU and its direct treatment costs for patients in intensive care unit (ICU) in Iran.Material and methods
In this retrospective study, medical records of 643 discharged patients from ICU of two selected hospitals were examined. The demographic and clinical data of all patients and data of resources and services usage for patients with PU were extracted through their records. Data analysis was done using logistic regression tests in SPSS 22 software. The cost of PU treatment was calculated for each grade of ulcer.Results
The findings showed that 8.9% of patients developed PU during their stay in ICU. Muscular paralysis (OR?=?5.1), length of stay in ICU (OR?=?4.0), diabetes (OR?=?3.5) age (OR?=?2.9), smoking (OR?=?2.1) and trauma (OR?=?1.4) were the most important risk factors of PU. The average cost of PU treatment varied from USD 12 for grade I PU to USD 66?834 for grade IV PUs. The total treatment costs for all studied patients with PU was estimated at USD 519?991.Conclusion
The cost of PU treatment is significant. Since the preventive measures are more cost-effective than therapeutic measures, therefore, effective preventive interventions are recommended. 相似文献3.
Cost‐Effectiveness and Cost‐Utility Analysis of Spinal Cord Stimulation in Patients With Failed Back Surgery Syndrome: Results From the PRECISE Study
下载免费PDF全文
![点击此处可从《Neuromodulation》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Furio Zucco MD Roberta Ciampichini MSc Angelo Lavano MD Amedeo Costantini MD Marisa De Rose MD Paolo Poli MD Gianpaolo Fortini MD Laura Demartini MD Enrico De Simone MD Valentino Menardo MD Piero Cisotto MD Mario Meglio MD Luciana Scalone PhD Lorenzo G. Mantovani DSc 《Neuromodulation》2015,18(4):266-276
4.
目的 了解解放军总医院抗震颤麻痹药物的应用情况与用药趋势。方法 采用世界卫生组织(WHO)推荐的以限定日剂量(DDD)为指标的分析方法,对2015-2017年解放军总医院抗震颤麻痹药物的销售金额、用药频度(DDDs)、日均费用(DDC)及排序比(B/A)等进行统计分析。结果 普拉克索、多巴丝肼和恩他卡朋的用药金额始终处于前3位,普拉克索的用药金额逐渐上升,卡比多巴/左旋多巴的用药金额逐渐下降;DDDs排序列前2位的是多巴丝肼和司来吉兰,多巴丝肼的DDDs逐年上升,一直处于第1位;2015-2016年各种抗震颤麻痹药物的DDC较为稳定,2016-2017年各种抗震颤麻痹药物的DDC开始略有下降;除普拉克索和恩他卡朋的B/A始终小于1.00,其他抗震颤麻痹药物的B/A均在1.00以上波动。结论 解放军总医院抗震颤麻痹药物的使用较为合理,其中多巴丝肼、普拉克索和司来吉兰具有很好的市场前景。 相似文献
5.
GIUSEPPE BORIANI MAURO BIFFI MAURIZIO RUSSO† MAURIZIO LUNATI‡ GIANLUCA BOTTO¶ ALESSANDRO PROCLEMER§ GIUSEPPE VERGARA WERNER RAHUE†† CRISTIAN MARTIGNANI RENATO RICCI† MASSIMO SANTINI† On Behalf of the SEARCH MI Registry Italian Investigators 《Pacing and clinical electrophysiology : PACE》2006,29(S2):S29-S34
Background: Large randomized trials show that in appropriately selected patients with left ventricular dysfunction, implantable cardioverter-defibrillators (ICDs) can improve overall survival at 2–5 years. Since direct implementation of the criteria used in the MADIT II and SCD-HeFT will lead to a marked rise in ICD implants, there is a growing fear that increased use of ICDs may cause a dramatic burden to health care systems. The ICD has traditionally been seen as an expensive form of treatment, which is difficult to accept at the first look. This is mainly due to the nonlinear character of the ICD investment, characterized by high initial expenditure, followed by a deferred pay-off in terms of clinical benefits. Cost-effectiveness analysis may help provide a different perspective on the problem of ICD cost, as may estimation of the daily cost of ICD treatment, assuming a time horizon of 5–7 years—a particularly interesting subject for further registry studies.
Methods and Results: Based on real expenditure data from 2002 to 2005, as recorded in the Search-MI Registry-Italian Sub-study of patients implanted on MADIT II indications, we estimated the daily costs associated with the device and leads. Over a 5–7 year time horizon, the average daily cost was estimated to be €4.60–€6.70. Translation of these figures into U.S. market conditions suggests a daily cost of around $7.90–$11.40.
Conclusions: These findings appear useful to help evaluate the affordability of ICD in comparison with other therapeutic options in a context of limited available economic resources. 相似文献
Methods and Results: Based on real expenditure data from 2002 to 2005, as recorded in the Search-MI Registry-Italian Sub-study of patients implanted on MADIT II indications, we estimated the daily costs associated with the device and leads. Over a 5–7 year time horizon, the average daily cost was estimated to be €4.60–€6.70. Translation of these figures into U.S. market conditions suggests a daily cost of around $7.90–$11.40.
Conclusions: These findings appear useful to help evaluate the affordability of ICD in comparison with other therapeutic options in a context of limited available economic resources. 相似文献
6.
7.
Diseases like rotavirus afflict both upper- and lower-income countries, but most serious illnesses and deaths occur among the latter. It is a vital public health issue that vaccines for these types of global diseases can recover research and development (R&D) costs from high-priced markets quickly so that manufacturers can offer affordable prices to lower-income nations. Cost recovery depends on how high R&D costs are, and this study attempts to replace high, unverified estimates with lower, more verifiable estimates for two new vaccines, RotaTeq (Merck) and Rotarix (GlaxoSmithKline or GSK), based on detailed searches of public information and follow-up interviews with senior informants. We also offer a new perspective on “cost of capital” as a claim for recovery from public bodies. Our estimates suggest that companies can recover all fixed costs quickly from affluent markets and thus can offer these vaccines to lower-income countries at prices they can afford. Better vaccines are a shared project between companies and public health agencies; greater transparency and consistency in reporting of R&D costs is needed so that fair prices can be established. 相似文献
8.
9.
A.M. Heugas A. Nummela M.A. Amorim V. Billat 《Journal of Science and Medicine in Sport》2007,10(5):280-287
It is difficult to interpret the training induced changes in middle-distance running, since numerous aerobic and anaerobic determinants of the performance are interdependent. Several aerobic and anaerobic tests are available but their results, particularly those from anaerobic tests, may be discordant, not providing univocal interpretation of training. The purpose of this study is to use a multidimensional approach to distinguish aerobic and anaerobic capacities assessed by two running tests on a track: the maximal anaerobic running test (MART) and V(O2max) tests. Eleven runners carried out two maximal tests on a synthetic track before and after a 4-week training period: (i) a maximal test to determine V(O2max), the velocity associated with V(O2max) (vV(O2max)) and the velocity at the lactate threshold (v(LT)), (ii) a maximal anaerobic running test to estimate anaerobic capacity. An all-out test run at v(LT)+50% of the difference between v(LT) and vV(O2max), known to be affected by both aerobic and anaerobic energy production, was used to test this approach. A principal components analysis (PCA) shows that two components (i.e., aerobic and anaerobic) explained 79% of the variation in the physiological variables. The PCA suggests that V(O2max) and MART tests assess the aerobic and the anaerobic capacities, respectively. In contrast, the performance in the all-out test is affected by both aerobic and anaerobic energy production. The PCA shows that v(LT) and DeltaP (difference between the maximal power of the MART and V(O2max)) are clear markers of the long-term endurance and the anaerobic capacity, respectively. This multidimensional approach can be a useful way to disentangle the aerobic and anaerobic components of track tests. 相似文献